Olympus Corp. (JP:7733)
:7733
Want to see JP:7733 full AI Analyst Report?
7733 Stock Chart & Stats
¥1583.50
¥60.50(2.58%)
At close: 4:00 PM EST
¥1583.50
¥60.50(2.58%)
Day’s Range― - ―
52-Week Range¥1,302.50 - ¥2,168.00
Previous CloseN/A
Volume4.23M
Average Volume (3M)3.67M
Market Cap
¥1.73T
Enterprise Value¥1.80T
Total Cash (Recent Filing)¥196.74B
Total Debt (Recent Filing)¥237.82B
Price to Earnings (P/E)38.6
Beta0.80
Next Earnings
May 12, 2026EPS Estimate
7.65Next Dividend Ex-DateN/A
Dividend Yield1.01%
Share Statistics
EPS (TTM)75.49
Shares Outstanding1,114,485,700
10 Day Avg. Volume4,971,740
30 Day Avg. Volume3,665,053
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)2.96
Price to Sales (P/S)2.23
P/FCF Ratio15.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,825.00Price Target Upside15.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)85.7
Revenue Forecast (FY)¥1.05T
Bulls Say, Bears Say
Bulls Say
High MarginsSustainably high gross and operating margins reflect differentiated, high-value endoscopy platforms and profitable consumables/services. This structural margin profile supports reinvestment in R&D, funds SG&A and remediation costs, and underpins long-term cash generation even with modest revenue growth.
Improving LeverageA markedly lower debt burden enhances financial flexibility for capital spending, regulatory remediation and strategic investments. Improved leverage reduces refinancing risk, preserves capacity for restructuring charges, and strengthens resilience across industry cycles over the next several quarters.
Installed Base Recurring RevenueA business model anchored by installed equipment drives steady consumables and service revenue, smoothing cycles tied to capital purchases. This recurring mix supports predictable lifetime customer value, margin stability and durable cash flows that are less volatile than pure capital-equipment sales.
Bears Say
Regulatory / FDA RiskActive FDA observations and remaining product remediation create persistent operational and compliance risk. Prolonged regulatory actions can limit new shipments, raise ongoing quality-control costs, and impair customer confidence, making revenue and margin recovery uncertain until fully resolved.
Volatile Free Cash FlowInconsistent cash conversion limits the firm's ability to reliably fund R&D, capital expenditure and restructuring without drawing on liquidity. Variability increases execution risk for multi-year programs and complicates predictable capital allocation, dividends, or opportunistic investments.
Commercial Execution & Growth CoolingExecution shortfalls in a core market and stalled top-line growth indicate structural go-to-market weaknesses. Even with strong products, failure to convert pipeline and regain share can restrain midterm revenue targets and make margin improvement and return-on-invested-capital harder to realize.
Olympus News
7733 FAQ
What was Olympus Corp.’s price range in the past 12 months?
Olympus Corp. lowest stock price was ¥1302.50 and its highest was ¥2168.00 in the past 12 months.
What is Olympus Corp.’s market cap?
Olympus Corp.’s market cap is ¥1.73T.
When is Olympus Corp.’s upcoming earnings report date?
Olympus Corp.’s upcoming earnings report date is May 12, 2026 which is in 2 days.
How were Olympus Corp.’s earnings last quarter?
Olympus Corp. released its earnings results on Feb 13, 2026. The company reported ¥12.87 earnings per share for the quarter, missing the consensus estimate of ¥23.057 by -¥10.187.
Is Olympus Corp. overvalued?
According to Wall Street analysts Olympus Corp.’s price is currently Undervalued.
Does Olympus Corp. pay dividends?
Olympus Corp. pays a Annually dividend of ¥30 which represents an annual dividend yield of 1.01%. See more information on Olympus Corp. dividends here
What is Olympus Corp.’s EPS estimate?
Olympus Corp.’s EPS estimate is 7.65.
How many shares outstanding does Olympus Corp. have?
Olympus Corp. has 1,114,485,700 shares outstanding.
What happened to Olympus Corp.’s price movement after its last earnings report?
Olympus Corp. reported an EPS of ¥12.87 in its last earnings report, missing expectations of ¥23.057. Following the earnings report the stock price went down -5.219%.
Which hedge fund is a major shareholder of Olympus Corp.?
Currently, no hedge funds are holding shares in JP:7733
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Olympus Corp.
Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.
7733 Company Deck
7733 Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presented a mix of significant near-term challenges—most notably product ship holds, FDA observations, one-off costs that reduced gross margin and a 2% revenue guidance downgrade—balanced against clear remediation plans, leadership actions, a majority of held products already released (70%), an asserted China recovery (≈5–6%), maintained midterm targets and a commitment to >100 bps margin expansion beginning FY2027. Near-term financial impact is material, but management articulated specific corrective actions and kept long-term targets unchanged.View all JP:7733 earnings summaries7733 Stock 12 Month Forecast
Average Price Target
¥1,825.00
▲(15.25% Upside)
Technical Analysis
Options Prices
Currently, No data available
---